Literature DB >> 22474227

Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension.

Eric D Austin1, Lijiang Ma, Charles LeDuc, Erika Berman Rosenzweig, Alain Borczuk, John A Phillips, Teresa Palomero, Pavel Sumazin, Hyunjae R Kim, Megha H Talati, James West, James E Loyd, Wendy K Chung.   

Abstract

BACKGROUND: Heritable and idiopathic pulmonary arterial hypertension (PAH) are phenotypically identical and associated with mutations in several genes related to transforming growth factor (TGF) beta signaling, including bone morphogenetic protein receptor type 2, activin receptor-like kinase 1, endoglin, and mothers against decapentaplegic 9. Approximately 25% of heritable cases lack identifiable mutations in any of these genes. METHODS AND
RESULTS: We used whole exome sequencing to study a 3-generation family with multiple affected family members with PAH, but no identifiable TGF beta mutation. We identified a frameshift mutation in caveolin-1 (CAV1), which encodes a membrane protein of caveolae abundant in the endothelium and other cells of the lung. An independent de novo frameshift mutation was identified in a child with idiopathic PAH. Western blot analysis demonstrated a reduction in caveolin-1 protein, while lung tissue immunostaining studies demonstrated a reduction in normal caveolin-1 density within the endothelial cell layer of small arteries.
CONCLUSIONS: Our study represents successful elucidation of a dominant Mendelian disorder using whole exome sequencing. Mutations in CAV1 are associated in rare cases with PAH. This may have important implications for pulmonary vascular biology, as well as PAH-directed therapeutic development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22474227      PMCID: PMC3380156          DOI: 10.1161/CIRCGENETICS.111.961888

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  28 in total

1.  Punch biopsy of the skin.

Authors:  Thomas J Zuber
Journal:  Am Fam Physician       Date:  2002-03-15       Impact factor: 3.292

2.  Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice.

Authors:  M Drab; P Verkade; M Elger; M Kasper; M Lohn; B Lauterbach; J Menne; C Lindschau; F Mende; F C Luft; A Schedl; H Haller; T V Kurzchalia
Journal:  Science       Date:  2001-08-09       Impact factor: 47.728

3.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.

Authors:  Z Deng; J H Morse; S L Slager; N Cuervo; K J Moore; G Venetos; S Kalachikov; E Cayanis; S G Fischer; R J Barst; S E Hodge; J A Knowles
Journal:  Am J Hum Genet       Date:  2000-07-20       Impact factor: 11.025

4.  Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.

Authors:  K B Lane; R D Machado; M W Pauciulo; J R Thomson; J A Phillips; J E Loyd; W C Nichols; R C Trembath
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

5.  Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities.

Authors:  B Razani; J A Engelman; X B Wang; W Schubert; X L Zhang; C B Marks; F Macaluso; R G Russell; M Li; R G Pestell; D Di Vizio; H Hou; B Kneitz; G Lagaud; G J Christ; W Edelmann; M P Lisanti
Journal:  J Biol Chem       Date:  2001-07-16       Impact factor: 5.157

6.  Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis.

Authors:  M W Geraci; M Moore; T Gesell; M E Yeager; L Alger; H Golpon; B Gao; J E Loyd; R M Tuder; N F Voelkel
Journal:  Circ Res       Date:  2001-03-30       Impact factor: 17.367

7.  Invasion activating caveolin-1 mutation in human scirrhous breast cancers.

Authors:  K Hayashi; S Matsuda; K Machida; T Yamamoto; Y Fukuda; Y Nimura; T Hayakawa; M Hamaguchi
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

8.  Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice.

Authors:  You-Yang Zhao; Yang Liu; Radu-Virgil Stan; Lian Fan; Yusu Gu; Nancy Dalton; Po-Hsien Chu; Kirk Peterson; John Ross; Kenneth R Chien
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

9.  Disruption of endothelial-cell caveolin-1alpha/raft scaffolding during development of monocrotaline-induced pulmonary hypertension.

Authors:  Rajamma Mathew; Jing Huang; Mehul Shah; Kirit Patel; Michael Gewitz; Pravin B Sehgal
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

Review 10.  Caveolin regulation of endothelial function.

Authors:  Richard D Minshall; William C Sessa; Radu V Stan; Richard G W Anderson; Asrar B Malik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-12       Impact factor: 5.464

View more
  168 in total

1.  Identification of Rare Variants in ATP8B4 as a Risk Factor for Systemic Sclerosis by Whole-Exome Sequencing.

Authors:  Li Gao; Mary J Emond; Tin Louie; Chris Cheadle; Alan E Berger; Nicholas Rafaels; Candelaria Vergara; Yoonhee Kim; Margaret A Taub; Ingo Ruczinski; Stephen C Mathai; Stephen S Rich; Deborah A Nickerson; Laura K Hummers; Michael J Bamshad; Paul M Hassoun; Rasika A Mathias; Kathleen C Barnes
Journal:  Arthritis Rheumatol       Date:  2016-01       Impact factor: 10.995

Review 2.  Redox biology in pulmonary arterial hypertension (2013 Grover Conference Series).

Authors:  Joshua P Fessel; James D West
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

3.  Mouse Genome-Wide Association Study of Preclinical Group II Pulmonary Hypertension Identifies Epidermal Growth Factor Receptor.

Authors:  Neil J Kelly; Josiah E Radder; Jeffrey J Baust; Christine L Burton; Yen-Chun Lai; Karin C Potoka; Brittani A Agostini; John P Wood; Timothy N Bachman; Rebecca R Vanderpool; Nadine Dandachi; Adriana S Leme; Alyssa D Gregory; Alison Morris; Ana L Mora; Mark T Gladwin; Steven D Shapiro
Journal:  Am J Respir Cell Mol Biol       Date:  2017-04       Impact factor: 6.914

Review 4.  Discovery of a murine model of clinical PAH: Mission impossible?

Authors:  Zhiyu Dai; You-Yang Zhao
Journal:  Trends Cardiovasc Med       Date:  2016-12-15       Impact factor: 6.677

Review 5.  Pulmonary Hypertension and ATP-Sensitive Potassium Channels.

Authors:  Conor McClenaghan; Kel Vin Woo; Colin G Nichols
Journal:  Hypertension       Date:  2019-05-28       Impact factor: 10.190

Review 6.  Epidemiology of pulmonary arterial hypertension.

Authors:  Xin Jiang; Zhi-Cheng Jing
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

Review 7.  The promise of whole-exome sequencing in medical genetics.

Authors:  Bahareh Rabbani; Mustafa Tekin; Nejat Mahdieh
Journal:  J Hum Genet       Date:  2013-11-07       Impact factor: 3.172

8.  Learning a Comorbidity-Driven Taxonomy of Pediatric Pulmonary Hypertension.

Authors:  Mei-Sing Ong; Mary P Mullen; Eric D Austin; Peter Szolovits; Marc D Natter; Alon Geva; Tianxi Cai; Sek Won Kong; Kenneth D Mandl
Journal:  Circ Res       Date:  2017-06-13       Impact factor: 17.367

Review 9.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

10.  Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.

Authors:  Rachel Damico; Todd M Kolb; Lidenys Valera; Lan Wang; Traci Housten; Ryan J Tedford; David A Kass; Nicholas Rafaels; Li Gao; Kathleen C Barnes; Raymond L Benza; James L Rand; Rizwan Hamid; James E Loyd; Ivan M Robbins; Anna R Hemnes; Wendy K Chung; Eric D Austin; M Bradley Drummond; Stephen C Mathai; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.